The estimated Net Worth of Ventures Iv, L.P.5 Am Co In... is at least $19.8 Million dollars as of 21 June 2019. Ventures In owns over 250,000 units of Crinetics Pharmaceuticals Inc stock worth over $4,794,372 and over the last 6 years Ventures sold CRNX stock worth over $15,040,753.
Sign up
Ventures In CRNX stock SEC Form 4 insiders trading
Ventures has made over 4 trades of the Crinetics Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Ventures sold 250,000 units of CRNX stock worth $5,550,000 on 21 June 2019.
The largest trade Ventures's ever made was selling 262,153 units of Crinetics Pharmaceuticals Inc stock on 22 January 2019 worth over $5,735,908. On average, Ventures trades about 156,398 units every 67 days since 2018. As of 21 June 2019 Ventures still owns at least 94,489 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Ventures In stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Crinetics Pharmaceuticals Inc
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen, and Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
What does Crinetics Pharmaceuticals Inc do?
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
What does Crinetics Pharmaceuticals Inc's logo look like?
Complete history of Ventures In stock trades at Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc executives and stock owners
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
R. Scott Struthers,
President, Chief Executive Officer, Director -
Alan Krasner,
Chief Medical Officer -
Marc Wilson,
Chief Financial Officer -
Dr. R. Scott Struthers Ph.D.,
Founder, Pres, CEO & Director -
Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
Chief Devel. Officer -
Marc J. C. Wilson,
CFO & Sec. -
Stephanie Okey,
Independent Director -
Wendall Wierenga,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
Jeff E. Knight,
Chief Operating Officer -
Stephen Kaldor,
Independent Director -
Weston Nichols,
Independent Director -
Peter Trainer,
Vice President - Clinical Endocrinology -
Camille Bedrosian,
Independent Director -
Adriana Cabre,
Vice President of Human Resources -
Ajay Madan,
Chief Development Officer -
Chris Robillard M.B.A.,
Chief Bus. Officer -
James Hassard,
Chief Commercial Officer -
Dr. Alan S. Krasner M.D.,
Chief Medical Officer -
Adriana Cabre M.B.A.,
Chief HR Officer -
Kevin Capps,
Head of Intellectual Property -
Dr. Alan S. Krasner,
Chief Medical Officer -
Garlan Adams,
Gen. Counsel -
Dr. Stephen F. Betz Ph.D.,
Founder & Chief Scientific Officer -
Dr. Yun-Fei Zhu,
Founder & VP of Chemistry -
Jeff E. Knight,
Chief Operating Officer -
Advisors Llcperceptive Life...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
James Hassard,
Chief Commercial Officer -
Jack Nielsen,
Director -
Coelho Rogerio Vivaldi,
-
Dana Pizzuti,
Chief Med and Dev Officer -
Stephen F. Betz,
Chief Scientific Officer -
Caren Deardorf,